Study to see which treatment works better - radiotherapy plus PCV chemotherapy or radiotherapy + temozolomide + additional temozolomide chemotherapy in patients with newly diagnosed anaplastic glioma or low grade glioma

What we are studying

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving temozolomide alone, radiation followed by PCV, or temozolomide together with radiation therapy followed by temozolomide is more effective in treating anaplastic glioma.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Study participant must have had surgery within more than two weeks prior to registration

What is involved

  • If the study participant is deemed eligible they will be randomized to one of two study groups - radiotherapy plus PCV chemotherapy or radiotherapy + temozolomide + additional temozolomide chemotherapy.

Compensation

Parking for all study related visits will be validated.

Contact Information

Study Coordinator
Ashley Fansler, RN
Email
arcarrol@wakehealth.edu
Phone
336-713-3539

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.